These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38898077)

  • 1. PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice.
    Jung J; Schneider EL; Zhang W; Song H; Zhang M; Chou W; Meher N; VanBrocklin HF; Barcellos-Hoff MH; Ozawa T; Gilbert MR; Santi DV
    Sci Rep; 2024 Jun; 14(1):14175. PubMed ID: 38898077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
    Mohammad AS; Griffith JI; Adkins CE; Shah N; Sechrest E; Dolan EL; Terrell-Hall TB; Hendriks BS; Lee H; Lockman PR
    Pharm Res; 2018 Jan; 35(2):31. PubMed ID: 29368289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity.
    Fontaine SD; Santi AD; Reid R; Smith PC; Ashley GW; Santi DV
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):225-229. PubMed ID: 31707444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
    Verreault M; Strutt D; Masin D; Anantha M; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2012 Feb; 158(1):34-43. PubMed ID: 22001870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft.
    Fontaine SD; Hann B; Reid R; Ashley GW; Santi DV
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):729-738. PubMed ID: 31321449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactive oxygen species responsive nanoprodrug to treat intracranial glioblastoma.
    Lee BS; Amano T; Wang HQ; Pantoja JL; Yoon CW; Hanson CJ; Amatya R; Yen A; Black KL; Yu JS
    ACS Nano; 2013 Apr; 7(4):3061-77. PubMed ID: 23557138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
    Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
    Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
    J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
    Verreault M; Strutt D; Masin D; Anantha M; Yung A; Kozlowski P; Waterhouse D; Bally MB; Yapp DT
    BMC Cancer; 2011 Apr; 11():124. PubMed ID: 21477311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Prodrug of Camptothecin for Enhanced Treatment of Glioblastoma Multiforme.
    Checa-Chavarria E; Rivero-Buceta E; Sanchez Martos MA; Martinez Navarrete G; Soto-Sánchez C; Botella P; Fernández E
    Mol Pharm; 2021 Apr; 18(4):1558-1572. PubMed ID: 33645231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
    Goldwirt L; Beccaria K; Carpentier A; Idbaih A; Schmitt C; Levasseur C; Labussiere M; Milane A; Farinotti R; Fernandez C
    J Neurooncol; 2015 Apr; 122(2):273-81. PubMed ID: 25794638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
    Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
    Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
    Chen PY; Ozawa T; Drummond DC; Kalra A; Fitzgerald JB; Kirpotin DB; Wei KC; Butowski N; Prados MD; Berger MS; Forsayeth JR; Bankiewicz K; James CD
    Neuro Oncol; 2013 Feb; 15(2):189-97. PubMed ID: 23262509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.
    Du S; Sarver JG; Trabbic CJ; Erhardt PW; Schroering A; Maltese WA
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):237-254. PubMed ID: 30426158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
    Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
    J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.
    Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
    Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
    BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
    Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
    Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
    Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
    Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.